N/A N=137 Sleep Specialty Consultation: Improving Management of Sleep Disorders
Sleep Disorders
Primary: Provider Adherence to Sleep Specialist Recommendations — 4; 0; 8; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Conversion Disorder
Primary: Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison — 4.18; 3.27; 3.85; 3.76 peak voxel z-score
Phase 4 N=40 Depression, Epinephrine, and Platelet Function
Major Depressive Disorder
Primary: Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8 — 5; 9; 2; 4 participants — p=.918
N/A N=46 Neurologic Injuries in Adults With Urea Cycle Disorders
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
N/A N=99 Fear, Gastrointestinal Distress, and Interoception: Physiological and Psychological Mechanisms in Eating Disorders
Feeding and Eating Disorders
Primary: Subjective Rating of Fear — -36.9444; -23.9219; -47.3611; 85.6250 units on scale*minutes — p=.879
N/A N=9 BRAIN, Symptoms, and Physical Activity in COPD
COPD · Chronic Musculoskeletal Pain
Primary: Cortical Thickness — 2.2 mm
N/A N=1,206 Epidemiology of Depression, Anxiety, and Cognitive Impairment
Depression · Anxiety · Cognitive Impairment
Primary: Participants With Depression by Patient Health Questionnaire - 9 — 177 participants
Phase 2 N=61 Heart Rate Variability in Response to Metformin Challenge
Fibromyalgia · Mitochondrial Diseases · Movement Disorders
Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
N/A N=24 The Effects of Respiratory Training on Voice
Muscle Tension Dysphonia
Primary: Post Training Lung Volume Initiation — 21.07; 27.04 % vital capacity relative to rest level — p=<0.0005
N/A N=38 Age-related Hearing Loss and Lexical Disorders
Alzheimer Disease · Presbycusis · Lexical Syntactic Disorder
Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
N/A N=50 Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function
Abnormality, Respiratory System · Autonomic Nervous System
Primary: FEV1 — 0.94; 1.08; 0.95; 1.09 percentage of predicted normal values
N/A N=61 Sex Steroids, Sleep, and Metabolic Dysfunction in Women
Polycystic Ovary Syndrome (PCOS) · Obstructive Sleep Apnea · Obesity
Primary: Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate — 3.13; 2.03; 4.66; 3.36 umol/min/L plasma — p=0.85
Phase 2 N=775 Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day (CPD) — 25.28; 19.95; 17.74 cigarettes per day — p=<0.0001
N/A N=47 Healthy Bodies, Healthy Kids
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
N/A N=300 Psychopathology, Disordered Eating, and Impulsivity as Predictors of Outcomes of Bariatric Surgery
Obesity
Primary: Percent Weight Change — 23.0; 26.2; 23.3 percent weight change
N/A N=40 Physiological Flow of Liquids Used in Dysphagia Management (Neuro)
Amyotrophic Lateral Sclerosis · Parkinson Disease · Dysphagia
Primary: Number of Participants With Residue of Concern (Observational) — 6; 6; 3; 6 Participants
N/A N=23 Neurobiological and Psychological Benefits of Exercise in Chronic Pain and PTSD
Chronic Musculoskeletal Pain · Posttraumatic Stress Disorder (PTSD) · Mild or Moderate Traumatic Brain Injury
Primary: Change From Baseline: PTSD Checklist-5 (PCL-5) — 15.64 units on a scale — p=.040
N/A N=158 Clinical Improvement and in Quality of Life-Functional Dyspepsia-
Psychogenic Dyspepsia
Primary: Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS) — 73.72; 65.31; 71.85; 64.89 units on a scale
N/A N=10 Network Dysregulation Among Individuals With Comorbid Tinnitus and PTSD
Stress Disorders, Post-Traumatic · Tinnitus
Primary: Change in Score on Clinician Administered PTSD Scale for the DSM-5 (CAPS-5) — 33.10; 16.13 score on a scale — p=0.01
N/A N=45 Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders
Psychomotor Retardation · Psychomotor Slowing · Schizophrenia and Related Disorders
Primary: Number of Responders at Week 3 — 4; 9; 0; 3 responders
Phase 3 N=80 Post Traumatic Stress Disorder (PTSD) Hyperarousal Symptoms Treated With Physiological Stress Management
Stress Disorders, Post-Traumatic
Primary: Change Scores for Criteria D Items on the CAPS Structured Clinical Interview — -1.20; -6.27 units on a scale — p=.27
N/A N=46 e-Mobile Tablet for People With Chronic Conditions
Fibromyalgia · Multiple Sclerosis · Osteoarthritis
Primary: Changes From Baseline in Physical Activity — 0.36; 0.31; 0.43; 0.76 units on a scale
N/A N=359 Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma
Chronic Pain
Primary: Numeric Rating Scales of Pain Over Past Week (11 Point Likert Scale) — 4.66; 3.80; 4.92; 3.30 units on a scale
N/A N=294 Comprehensive vs. Assisted Management of Mood and Pain Symptoms
Pain · Depression · Anxiety
Primary: Composite Z-score of Pain-anxiety-depression Severity — -0.52; -0.65 units on a scale
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
Phase 4 N=183 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
Depression · Generalized Anxiety Disorder · Panic Disorder
Primary: Change in Mental Health-related Quality of Life From Baseline to 24 Weeks — 8.87; 8.39 units on a scale — p=0.002
Phase 2 N=8 Healthy Heart Habits
Acute Coronary Syndrome · Depression
Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale